Indian benchmark indices ended their two-day winning streak on Monday, with the Sensex declining 372 points (0.48%) to close at 76,728.37 and the Nifty 50 dropping 110 points (0.46%) to settle at 23,946.25. According to reports from MarketSmith India, investor sentiment turned cautious following renewed geopolitical friction in West Asia, as fresh military exchanges between the U.S. and Iran pushed crude oil prices higher, prompting profit-booking across major sectors. The broader market also felt the impact, with the Nifty Midcap 100 dropping 0.37% and the Smallcap 100 index declining 0.62%. Market breadth remained weak, with the advance-decline ratio at 1,330 advances against 2,036 declines, indicating broader participation on the downside.
From a sectoral perspective, defensive buying emerged in Pharma and Metals, which managed to close in the green, while interest-rate-sensitive and cyclical sectors bore the brunt of the selloff. As reported by MarketSmith India, Auto sector declined 2.08%, Media fell 1.32%, Oil & Gas dropped 1.18%, and IT decreased 1.07%. Conversely, defensive sectors outperformed with Pharma gaining 1.03%, Health Care rising 0.94%, and Metal advancing 0.80%. The Nifty 50 breached its immediate psychological threshold of 24,000, signaling an increase in near-term selling pressure and potentially shifting the index into a brief consolidation phase after recent gains.
MarketSmith India recommends Multi Commodity Exchange of India Limited as a buy at current price of ₹2,900, with a buy range of ₹2,871–2,915 and target price of ₹3,250 in two to three months. According to the recommendation, the stock is recommended due to its leading commodity exchange position, asset-light business model, high operating leverage, and beneficiary status of rising trading volumes. The company's key metrics include P/E ratio: NA, 52-week high: ₹3,480.00, and volume: ₹2,536.73 crore. Technical analysis shows trendline breakout pattern with stop loss at ₹2,780.
The second recommendation is Zydus Wellness Limited at current price of ₹569, with buy range of ₹563–572 and target price of ₹640 in two to three months. As reported by MarketSmith India, the recommendation is based on the company's strong portfolio of health-focused brands, leading presence in wellness products, and asset-light business model. Key metrics include P/E ratio: 67.15, 52-week high: ₹577.50, and volume: ₹881.13 crore. The technical analysis shows flat base pattern breakout with stop loss at ₹537.
From a technical perspective, the Nifty 50 continues to consolidate between the 50- and 100-DMA for the last 9-10 trading sessions, indicating a phase of consolidation and indecision. According to MarketSmith India analysis, the index remains positioned above a key downward-sloping trendline, with the 23,800–23,650 zone being a crucial area to monitor. The Relative Strength Index (RSI) is placed at 53.9, remaining above the neutral 50 mark but turning slightly lower, while the MACD remains above its signal line. A decisive close above the 100-DMA near 24,200 would be a significant technical development, potentially paving the way for advance toward the 24,350–24,600 zone.
